Verve Therapeutics (VERV) Stock Forecast, Price Target & Predictions
VERV Stock Forecast
Verve Therapeutics stock forecast is as follows: an average price target of $14.00 (represents a 171.32% upside from VERV’s last price of $5.16) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
VERV Price Target
The average price target for Verve Therapeutics (VERV) is $14.00 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $14.00 to $14.00. This represents a potential 171.32% upside from VERV's last price of $5.16.
VERV Analyst Ratings
According to 8 Wall Street analysts, Verve Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for VERV stock is 0 'Strong Buy' (0.00%), 5 'Buy' (62.50%), 2 'Hold' (25.00%), 1 'Sell' (12.50%), and 0 'Strong Sell' (0.00%).
Verve Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 06, 2024 | Mitchell Kapoor | H.C. Wainwright | $14.00 | $6.32 | 121.69% | 171.32% |
| Apr 03, 2024 | Kostas Biliouris | BMO Capital | $30.00 | $8.57 | 250.06% | 481.40% |
| Dec 15, 2022 | Goldman Sachs | $13.00 | $22.61 | -42.50% | 151.94% |
The latest Verve Therapeutics stock forecast, released on Nov 06, 2024 by Mitchell Kapoor from H.C. Wainwright, set a price target of $14.00, which represents a 121.69% increase from the stock price at the time of the forecast ($6.32), and a 171.32% increase from VERV last price ($5.16).
Verve Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 2 |
| Avg Price Target | - | $14.00 | $22.00 |
| Last Closing Price | $5.16 | $5.16 | $5.16 |
| Upside/Downside | -100.00% | 171.32% | 326.36% |
In the current month, the average price target of Verve Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Verve Therapeutics's last price of $5.16. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 06, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 09, 2024 | RBC Capital | Outperform | Outperform | Hold |
| May 09, 2024 | Jefferies | Buy | Buy | Hold |
| Apr 08, 2024 | H.C. Wainwright | Buy | Initialise | |
| Apr 03, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Apr 02, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Feb 01, 2023 | Cantor Fitzgerald | Neutral | Initialise | |
| Dec 15, 2022 | Goldman Sachs | Sell | Initialise | |
| Oct 06, 2022 | Credit Suisse | Neutral | Initialise | |
| Aug 25, 2022 | Telsey Advisory | Buy | Upgrade | |
| Feb 18, 2022 | RBC Capital | Outperform | Initialise |
Verve Therapeutics's last stock rating was published by H.C. Wainwright on Nov 06, 2024. The company gave VERV a "Buy" rating, the same as its previous rate.
Verve Therapeutics Financial Forecast
Verve Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $5.14M | $3.12M | $2.09M | $1.40M | $1.01M | $929.00K |
| Avg Forecast | $3.72M | $3.37M | $2.97M | $3.17M | $3.57M | $2.75M | $2.40M | $2.11M | $3.77M | $963.67K | $672.67K | $450.00K | $730.29K | $833.33K |
| High Forecast | $3.72M | $3.37M | $2.97M | $3.17M | $3.96M | $2.77M | $2.40M | $2.11M | $4.31M | $963.83K | $672.67K | $450.00K | $730.29K | $833.33K |
| Low Forecast | $3.72M | $3.37M | $2.97M | $3.17M | $3.17M | $2.72M | $2.40M | $2.11M | $3.23M | $963.50K | $672.67K | $450.00K | $730.29K | $833.33K |
| # Analysts | 1 | 1 | 1 | 3 | 4 | 2 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | 1.37% | 3.23% | 3.11% | 3.12% | 1.39% | 1.11% |
Verve Therapeutics's average Quarter revenue forecast for Mar 24 based on 4 analysts is $2.11M, with a low forecast of $2.11M, and a high forecast of $2.11M. VERV's average Quarter revenue forecast represents a -59.02% decrease compared to the company's last Quarter revenue of $5.14M (Dec 23).
Verve Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 4 | 2 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | $-52.43M | $-52.33M | $-58.58M | $-58.26M | $-46.78M | $-43.86M |
| Avg Forecast | $743.25K | $674.60K | $594.60K | $634.60K | $713.30K | $549.23K | $480.29K | $421.63K | $753.02K | $192.73K | $134.53K | $90.00K | $146.06K | $166.67K |
| High Forecast | $743.25K | $674.60K | $594.60K | $634.60K | $792.55K | $554.24K | $480.34K | $421.64K | $861.68K | $192.77K | $134.53K | $90.00K | $146.06K | $166.67K |
| Low Forecast | $743.25K | $674.60K | $594.60K | $634.60K | $633.12K | $544.21K | $480.25K | $421.61K | $646.26K | $192.70K | $134.53K | $90.00K | $146.06K | $166.67K |
| Surprise % | - | - | - | - | - | - | - | - | -69.63% | -271.54% | -435.45% | -647.33% | -320.32% | -263.16% |
undefined analysts predict VERV's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Verve Therapeutics's previous annual EBITDA (undefined) of $NaN.
Verve Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 4 | 2 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 |
| Net Income | - | - | - | - | - | - | - | - | $-48.35M | $-45.76M | $-53.98M | $-45.69M | $-41.09M | $-46.52M |
| Avg Forecast | $-63.53M | $-64.59M | $-63.10M | $-62.06M | $-57.88M | $-57.86M | $-57.32M | $-59.37M | $-63.83M | $-76.57M | $-77.71M | $-65.07M | $-60.99M | $-62.48M |
| High Forecast | $-63.53M | $-64.59M | $-63.10M | $-52.45M | $-44.83M | $-57.86M | $-57.32M | $-59.37M | $-55.85M | $-76.57M | $-77.71M | $-65.07M | $-60.99M | $-62.48M |
| Low Forecast | $-63.53M | $-64.59M | $-63.10M | $-76.05M | $-73.36M | $-57.86M | $-57.32M | $-59.37M | $-67.82M | $-76.57M | $-77.71M | $-65.07M | $-60.99M | $-62.48M |
| Surprise % | - | - | - | - | - | - | - | - | 0.76% | 0.60% | 0.69% | 0.70% | 0.67% | 0.74% |
Verve Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. VERV's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Verve Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 4 | 2 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 |
| SG&A | - | - | - | - | - | - | - | - | $10.76M | $11.69M | $13.42M | $12.55M | $11.44M | $9.59M |
| Avg Forecast | $19.76M | $17.93M | $15.81M | $16.87M | $18.96M | $14.60M | $12.77M | $11.21M | $20.02M | $5.12M | $3.58M | $2.39M | $3.88M | $4.35M |
| High Forecast | $19.76M | $17.93M | $15.81M | $16.87M | $21.07M | $14.73M | $12.77M | $11.21M | $22.91M | $5.12M | $3.58M | $2.39M | $3.88M | $4.35M |
| Low Forecast | $19.76M | $17.93M | $15.81M | $16.87M | $16.83M | $14.47M | $12.77M | $11.21M | $17.18M | $5.12M | $3.58M | $2.39M | $3.88M | $4.35M |
| Surprise % | - | - | - | - | - | - | - | - | 0.54% | 2.28% | 3.75% | 5.25% | 2.95% | 2.20% |
Verve Therapeutics's average Quarter SG&A projection for Mar 24 is $11.21M, based on 4 Wall Street analysts, with a range of $11.21M to $11.21M. The forecast indicates a 4.13% rise compared to VERV last annual SG&A of $10.76M (Dec 23).
Verve Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 4 | 2 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 |
| EPS | - | - | - | - | - | - | - | - | $-0.69 | $-0.72 | $-0.87 | $-0.74 | $-0.67 | $-0.81 |
| Avg Forecast | $-0.75 | $-0.76 | $-0.75 | $-0.73 | $-0.68 | $-0.68 | $-0.68 | $-0.70 | $-0.75 | $-0.90 | $-0.92 | $-0.77 | $-0.72 | $-0.74 |
| High Forecast | $-0.75 | $-0.76 | $-0.75 | $-0.62 | $-0.53 | $-0.68 | $-0.68 | $-0.70 | $-0.66 | $-0.90 | $-0.92 | $-0.77 | $-0.72 | $-0.74 |
| Low Forecast | $-0.75 | $-0.76 | $-0.75 | $-0.90 | $-0.87 | $-0.68 | $-0.68 | $-0.70 | $-0.80 | $-0.90 | $-0.92 | $-0.77 | $-0.72 | $-0.74 |
| Surprise % | - | - | - | - | - | - | - | - | 0.91% | 0.80% | 0.95% | 0.96% | 0.93% | 1.09% |
According to undefined Wall Street analysts, Verve Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to VERV previous annual EPS of $NaN (undefined).
Verve Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| EDIT | Editas Medicine | $1.52 | $10.20 | 571.05% | Buy |
| PRME | Prime Medicine | $2.91 | $17.25 | 492.78% | Buy |
| IPSC | Century Therapeutics | $1.17 | $5.00 | 327.35% | Buy |
| SANA | Sana Bio | $1.91 | $8.00 | 318.85% | Buy |
| NTLA | Intellia Therapeutics | $13.13 | $53.00 | 303.66% | Buy |
| RLAY | Relay Therapeutics | $4.50 | $18.00 | 300.00% | Buy |
| VERV | Verve Therapeutics | $5.61 | $14.00 | 149.55% | Buy |
| BEAM | Beam Therapeutics | $28.58 | $55.00 | 92.44% | Buy |
| ADPT | Adaptive Bio | $6.52 | $12.33 | 89.11% | Hold |
| CRSP | CRISPR Therapeutics | $44.63 | $77.50 | 73.65% | Buy |
| CRBU | Caribou Biosciences | $1.94 | $3.00 | 54.64% | Buy |
| BPMC | Blueprint Medicines | $96.48 | $122.60 | 27.07% | Buy |